Shuganning injection entered the "Clinical Pathway Interpretation" (2018 edition of the digestive disease fascicle)-won the "cholestatic jaundice" and "drug-induced liver injury" clinical treatment program recommend medication

Entrusted by the National Health and Health Commission (formerly the National Health and Family Planning Commission), the "Interpretation of Clinical Pathways (2018 Edition · Digestive Diseases)" compiled by the Chinese Academy of Medical Sciences was officially announced recently. Our company independently developed the application of liver disease treatment drug "Shuganning injection" in the market."Cholestatic jaundice" and "drug-induced liver injury"The clinical treatment plan has been particularly recommend applied, which is another achievement of our company's adherence to the scientific research concept of "quality and safety, innovative development", and highlights the active encouragement and support of the academic community for the application of Chinese patent medicine preparations in the field of liver disease treatment.

"Shuganning Injection" is a special recommend drug for "cholestatic jaundice" and "drug-induced liver injury", which shows that since the preparation was put on the market, it has been used in the treatment of two major "liver injury" diseases other than "viral hepatitis". The safety and effectiveness of its basic research and clinical scientific research have also been actively recognized and affirmed by the industry, shuganning injection, as a Chinese patent medicine preparation, has the application value and development prospect in the clinical practice of treating various liver diseases or hepatitis.

It is hoped that with the help of this "Shuganning Injection" selected in the "Clinical Pathway Interpretation" (2018 Edition, Digestive Disease Volume) to recommend a medication opportunity, it can help medical institutions or clinicians to purchase and use more rationally and safely. Our company will, as always, adhere to the guidance of science and technology, actively carry out clinical research, constantly enrich the results of clinical application, serve the treatment of liver diseases, and provide better, safer and more effective drug choices for clinical use.